Zimmer Biomet Holdings Inc. shares climbed 4.5% in pre-open trading today following publication of the company's second-quarter 2026 financial results. Management released the quarterly figures ahead of a conference call scheduled for 8:30 a.m. ET.
Analysts had expected diluted earnings per share of $2.01, a projection that implied a year-over-year decline, and revenue in the range of $2.13 billion to $2.14 billion, which represented roughly 2.5% to 2.9% growth. The company exceeded those consensus estimates, continuing a recent pattern of outperformance: Zimmer Biomet has beaten consensus EPS expectations in each of the prior four quarters, with an average positive surprise of nearly 5% over that span.
The results arrived against a backdrop of shifting analyst sentiment. On July 28, UBS upgraded the stock from Sell to Buy and set a $115 price target. That target sits well above prevailing share prices and signals increased conviction from at least one major analyst that the company’s ongoing transformation efforts and its orthopedic franchise may be undervalued.
Heading into the earnings release, the average analyst price target was near $99, already above the previous trading session's close. Following the results, the consensus price target has inched higher toward $103, indicating incremental optimism about Zimmer Biomet’s margin and growth trajectory.
Sector dynamics also provided a supportive context. Recent second-quarter reports from peers CONMED and Baxter beat estimates and sparked rallies in their respective post-earnings sessions, offering a constructive read-through for Zimmer Biomet’s orthopedic and surgical device businesses.
Taken together, a quarter that cleared analysts’ tempered expectations, a prominent analyst upgrade, and favorable peer results combined to drive the pre-market surge in ZBH. The rise pushed shares closer to the $100 mark and reduced the distance to the stock’s 52-week high of $108.29.
Summary
Zimmer Biomet beat consensus Q2 EPS and revenue expectations, extending a multi-quarter streak of EPS outperformance. A UBS upgrade to Buy and positive earnings from sector peers strengthened investor sentiment, contributing to a 4.5% pre-market rally and moves toward the $100 price level.
Key points
- The company beat EPS and revenue estimates for Q2 2026 and maintained a streak of quarterly EPS surprises averaging nearly 5%.
- UBS upgraded ZBH to Buy from Sell on July 28 and set a $115 price target, bringing fresh analyst conviction.
- Positive results from fellow healthcare equipment names such as CONMED and Baxter provided a constructive sector backdrop that likely supported Zimmer Biomet’s shares.
Risks and uncertainties
- Consensus estimates prior to the report were modest, so beating those tempered expectations may not indicate a stronger long-term trend without further confirmation from results and commentary during the company call (impacts healthcare equipment and medical device sectors).
- The market reaction is influenced by analyst targets and peer performance; any reversal in analyst sentiment or weaker results from sector peers could weigh on the stock (impacts investor sentiment in healthcare equipment and supplies).